Scheen A J, Mathieu C
Université de Liège, Belgique.
Rev Med Liege. 2012 Dec;67(12):623-31.
The pharmacological therapy of type 2 diabetes has become increasingly complex and the goals are now more diverse and, in general, more stringent. The glycaemic target (glycated haemoglobin or HbA1c) and the medications to be prescribed to reach it should be selected according to the individual characteristics of the patient and, if possible, in agreement with him/her. The most relevant criteria to be taken into account are the glucose-lowering efficacy, the risk of hypoglycaemia, the effect on body weight, the side effects and the costs. We summarize here the strategy proposed in the joint "position statement" published in 2012 by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). We will more particularly focus our attention on the practical aspects useful for the clinician.
2型糖尿病的药物治疗已变得日益复杂，目前的治疗目标更多样化，总体而言也更严格。血糖目标（糖化血红蛋白或HbA1c）以及为实现该目标而开具的药物应根据患者的个体特征来选择，并且如果可能的话，要与患者达成一致。需要考虑的最相关标准包括降糖疗效、低血糖风险、对体重的影响、副作用和成本。在此，我们总结美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）于2012年联合发表的“立场声明”中提出的策略。我们将更特别地关注对临床医生有用的实际方面。
